

Table S1. Dose reduction schema for *nab*-paclitaxel and docetaxel

	Initial dose	Level 1	Level 2	Level 3
<i>Nab</i> -Paclitaxel	150 mg/m ²	125 mg/m ²	100 mg/m ²	80 mg/m ²
Docetaxel	75 mg/m ²	60 mg/m ²	50 mg/m ²	Not applicable

Table S2. Dose reduction criteria for *nab*-paclitaxel and docetaxel

Toxicity	Event	<i>Nab</i> -Paclitaxel	Docetaxel
Neutropenia	≥ Grade 4 for consecutive ≥ 7 days	1 level	1 level
Thrombocytopenia	≥ Grade 3	1 level	1 level
Non-hematologic toxicity	≥ Grade 3	1 level	1 level
Other	Dose reduction criteria during the step 3	Discontinue	-
Other	Dose reduction criteria during the step 2	-	Discontinue
Other	Cases in which the investigator has determined that dose reduction is necessary	1 level	1 level

Table S3. Dose interruption criteria within treatment cycle

Toxicity	<i>Nab-paclitaxel and docetaxel</i>
Neutropenia	≥ Grade 4 for consecutive ≥ 7 days
Thrombocytopenia	≥ Grade 3
Non-hematologic toxicity	≥ Grade 3
Other	Cases in which the investigator has determined that dose interruption is necessary

Table S4. Criteria to start next cycle for *nab*-paclitaxel and docetaxel

	Criteria
Hemoglobin	≥ 8.0 g/dL
Neutrophil count	≥ 1500 / μ L
Platelet count	≥ 75000 / μ L
Total bilirubin	≤ 1.5 mg/dL
Aspartate aminotransferase or alanine aminotransferase	≤ 100 IU/L
Serum creatinine	≤ 1.5 mg/dL
Non-hematological toxicity	\leq Grade2